The online version of this article (https://doi.org/10.1007/s40121-018-0186-1) contains supplementary material, which is available to authorized users.
To view enhanced content for this article go to http://www.medengine.com/Redeem/104B4F6021959470.
To increase understanding of the epidemiology, risks, consequences and resource utilization of Clostridium difficile infection (CDI) in Japan, a systematic literature review was undertaken of relevant publications from January 2006 to November 2017. Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and methods, 55 articles met the criteria for full review. The majority (58%) of studies were from a single site, with the most recent data from 2015. The incidence, reported prevalence and recurrence rate of CDI in Japan were 0.8–4.71/10,000 patient-days, 0.3–5.5/1000 patients and 3.3–27.3%, respectively, and varied according to setting, population, CDI definition and detection method. Most C. difficile isolates associated with CDI in Japan were toxin A+B+, with a low level of C. difficile binary toxin-positive (CDT+) strains (0–6.8% reported across studies). The most common C. difficile PCR ribotypes associated with infection in Japan were smz/018, 002, 052 and 369. Data regarding the impact of CDI on length of hospital stay were limited. Reported all-cause mortality in patients with CDI ranged from 3.4 to 15.1% between 2007 and 2013. Two studies assessed risk factors for CDI recurrence, identifying malignant disease, intensive care unit hospitalization and use of proton pump inhibitors as factors increasing the risk of initial and/or recurrent CDI. No study analyzed initial CDI treatment in relation to recurrence. More comprehensive surveillance and coordinated studies are needed to map trends, understand risk factors, and recognize the extent and impact of CDI in Japanese patients.
Astellas Pharma, Inc.
Plain language summary available for this article.
Supplementary material 1 (PDF 184 kb)40121_2018_186_MOESM1_ESM.pdf
Chakra CNA, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS ONE. 2014;9:e107420. CrossRef
Collins DA, Hawkey PM, Riley TV. Epidemiology of Clostridium difficile infection in Asia. Antimicrob Resist Infect Control [Internet]. 2013;2:21. http://aricjournal.biomedcentral.com/articles/10.1186/2047-2994-2-21.
Shionogi & Co. Antitrichomonal agent, Flagyl ®—approval for additional indication for amoebic dysentery, giardiasis, anaerobic infection and infectious enteritis [Internet]. 2012 [cited 2017 Jun 7]. http://www.shionogi.co.jp/en/company/news/2012/pmrltj0000000wim-att/e_120810-2.pdf.
Pfizer Inc. Acquired manufacturing and marketing approval for anaerobic bacterial infection treatment agent “Anemetro ® IV infusion solution 500 mg” [Internet]. 2014 [cited 2017 Jun 7]. http://www.pfizer.co.jp/pfizer/company/press/2014/2014_07_04.html.
Onishi K, Somoda Y, Imamura A, Iwabuchi C, Okuda MNT. JAID/JSC infection treatment guideline 2015. Intestinal infection. Jpn J Chemother. 2016;64:31–65.
CEBM. Oxford Centre for Evidence-based Medicine—Levels of Evidence (March 2009) [Internet]. Cent. Evidence-Based Med. 2009 [cited 2017 Feb 23]. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/.
Cairns MD, Preston MD, Hall CL, Gerding DN, Hawkey PM, Kato H, et al. Correction for Cairns et al., “Comparative genome analysis and global phylogeny of the toxin variant Clostridium difficile PCR ribotype 017 reveals the evolution of two independent sublineages”. J Clin Microbiol. 2017;55:1971.
Kobayashi K, Sekiya N, Ainoda Y, Kurai H, Imamura A. Adherence to clinical practice guidelines for the management of Clostridium difficile infection in Japan: a multicenter retrospective study. Eur J Clin Microbiol Infect Dis Germany. 2017;36:1947–53. CrossRef
Suzuki H, Senda J, Yamashita K, Tokuda Y, Kanesaka Y, Kotaki N, et al. Impact of intensive infection control team activities on the acquisition of methicillin-resistant Staphylococcus aureus, drug-resistant Pseudomonas aeruginosa and the incidence of Clostridium difficile-associated disease. J Infect Chemother. 2013;19:1047–52. CrossRefPubMed
Hosokawa K, Takami A, Tsuji M, Araoka H. Relative incidences and outcomes of Clostridium difficile infection following transplantation of unrelated cord blood, unrelated bone marrow, and related peripheral blood in adult patients: a single institute study. Transpl Infect Dis. 2014;16:412–20. CrossRefPubMed
Roughead EE, Chan EW, Choi N-K, Griffiths J, Jin X-M, Lee J, et al. Proton pump inhibitors and risk of Clostridium difficile infection: a multi-country study using sequence symmetry analysis. Expert Opin Drug Saf Engl. 2016;15:1589–95. CrossRef
Mizui T, Teramachi H, Tachi T, Tamura K, Shiga H, Komada N, et al. Risk factors for Clostridium difficile-associated diarrhea and the effectiveness of prophylactic probiotic therapy. Pharmazie. 2013;68:706–10. PubMed
Ogami N, Yoshida J, Ishimaru T, Kikuchi T, Matsubara N, Ueno T, et al. Is Clostridium difficile infection influenced by antimicrobial use density in wards? Jpn J Antibiot. 2013;66:87–95. PubMed
Oshima T, Wu L, Li M, Fukui H, Watari J, Miwa H. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis. J Gastroenterol Jpn. 2018;53:84–94. CrossRef
Iwashima Y, Nakamura A, Kato HH, Kato HH, Wakimoto Y, Wakiyama N, et al. A retrospective study of the epidemiology of Clostridium difficile infection at a University Hospital in Japan: genotypic features of the isolates and clinical characteristics of the patients. J Infect Chemother. 2010;16:329–33. CrossRefPubMed
Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis [Internet]. 2007;45:302–7. http://www.ncbi.nlm.nih.gov/pubmed/17599306.
Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis. 2014;14:1208–19. CrossRefPubMed
Durkin MJ, Baker AW, Dicks KV, Lewis SS, Chen LF, Anderson DJ, et al. A comparison between National Healthcare Safety Network laboratory-identified event reporting versus traditional surveillance for Clostridium difficile infection. Infect Control Hosp Epidemiol. 2015;36:125–31. CrossRefPubMedPubMedCentral
Reeves JS, Evans ME, Simbartl LA, Kralovic SM, Kelly AA, Jain R, et al. Clostridium difficile infections in veterans health administration long-term care facilities. Infect Control Hosp Epidemiol. [Internet]. 2016 [cited 2017 Feb 23];37:295–300. http://www.ncbi.nlm.nih.gov/pubmed/26686361.
Organisation for Economic Co-operation and Development. Length of hospital stay [Internet]. 2016 [cited 2017 Jun 26]. https://data.oecd.org/healthcare/length-of-hospital-stay.htm.
Ministry of Health Labour and Welfare. Summary of patient survey 2014. [Internet]. 2015 [cited 2017 Jul 24]. http://www.mhlw.go.jp/english/database/db-hss/dl/sps_2014_03.pdf.
Agency for Healthcare Research and Quality (AHRQ). HCUP fast stats—trends in inpatient stays 2005-2014 [Internet]. 2014 [cited 2017 Jul 24]. https://www.hcup-us.ahrq.gov/faststats/NationalTrendsServlet.
Collins DA. Epidemiology of Clostridium difficile infection in the Asia-Pacific region [Internet]. The University of Western Australia; 2016. http://research-repository.uwa.edu.au/files/11692621/THESIS_DOCTOR_OF_PHILOSOPHY_COLLINS_Deirdre_Anne_2016.pdf.
Hata H, Yamaguchi T, Hasegawa S, Nomura A, Hida K. Oral and parenteral versus parenteral antibiotic prophylaxis in elective laparoscopic colorectal surgery (JMTO PREV 07-01): a phase 3, multicenter, open-label. Random Trial Ann Surg. 2016;263:1085–91.
Watanabe M, Hitomi S, Sawahata T. Nosocomial diarrhea caused by Clostridium perfringens in the Tsukuba-Tsuchiura district. Jpn J Infect Chemother. 2008;14:228–31. CrossRef
Kikkawa H, Hitomi S, Watanabe M. Prevalence of toxin A-nonproducing/toxin-B-producing Clostridium difficile in the Tsukuba-Tsuchiura district. Jpn J Infect Chemother. 2007;13:35–8. CrossRef
Yuhashi K, Yagihara Y, Misawa Y, Sato T, Saito R, Okugawa S, et al. Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients. Infect Drug Resist. 2016;27:93–9.
Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–55. CrossRefPubMed
- The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review
Thomas V. Riley
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II